Having a better understanding of what things are associated with LCHADD retinopathy can provide insight towards developing treatment. During this presentation, Dr. Gillingham will provide an update on the current results of a natural history study of 40 patients with LCHADD. She will also discuss what factors are associated with retinal structure and function, and how blood biomarkers or genetics might be related. Lastly, Dr. Gillingham will update our FAOD community about her lab’s efforts to treat retinopathy in an LCHADD mouse.
MitoAction welcomes Dr. David Holtzman to discuss “dysautonomia”. Dysautonomia is a failure of the autonomic nervous system to regulate certain body functions, such as...
Join MitoAction in an informative and exciting discussion with disability advocate and attorney Valerie Powers Smith as she brings to light issues regarding health...
Join us with Stealth BioTherapeutics CEO Travis Wilson and others from the Stealth BT team for a live update from Stealth BT (click here...
